Preexisting cardiovascular abnormalities including high waist circumference (≥88 cm), hypertension (>130/85 mm Hg), and self-reported history of diabetes and/or elevated cholesterol are an important predictor of outcomes among both women with and without cancer in the Women’s Health Initiative.

The use of adjuvant chemotherapy to treat localized, resectable STSs leads to improved survival outcomes. A multimodal approach should be considered during the therapeutic course.

Olaparib did not reveal radiographic response for patients with isocitrate dehydrogenase 1 (IDH1)– and IDH2-mutant cholangiocarcinoma. However, prolonged disease control was seen in a subset of patients, which correlated with lower tumor 2-hydroxyglutarate levels and prior treatment with an IDH inhibitor.

The authors investigated the prognostic impact of pretransplantation molecular measurable residual disease in adult patients with acute myeloid leukemia who had lysine methyltransferase 2a rearrangements. The results demonstrated that the presence of lysine methyltransferase 2a-rearranged measurable residual disease independently predicts posttransplantation mortality and relapse risk, providing a basis for tailored therapeutic strategies in high-risk patients.

Regardless of race, families preferred comfort care over medically intense end-of-life care while also wanting to continue chemotherapy. Parents prioritized quality care that allowed flexibility and focused on quality time with their child. Regular access to their care team was emphasized more than a specific location of death.

This study aims to examine the association of access to primary care with mortality in excess of patients with the 10 most frequent cancers in France, while controlling for socioeconomic deprivation. Patients living in areas with less access to primary care had a greater mortality in excess for some very common cancer sites like breast (women), lung (men), liver (men and women), and colorectal cancer (men), representing 46% of patients diagnosed in our sample.

In the Women’s Health Initiative Trans-Omics for Precision Medicine study, participants with clonal hematopoiesis of indeterminate potential (CHIP) had higher breast cancer incidence and a higher colorectal cancer mortality than women without CHIP. The presence of autosomal mosaic chromosomal alterations with >5% cell fraction was associated with higher incidence of breast cancer but no other cancers.

In this prospective study of hormone-naive men who were eugonadal and did not have diabetes, 24 weeks of androgen deprivation therapy (ADT) for prostate cancer (PCa) was not associated with worsening of hepatic or skeletal muscle insulin resistance despite a substantial increase in fat mass. These findings have relevance for both physicians and patients when determining treatment for PCa and suggest that a short course of ADT may not worsen metabolic risk in patients without pre-existing diabetes.

Several clinical trials published this past year have contributed to significant advances in thoracic oncology. Here, the focus is on targeted therapy advances reported in 2023 that are impacting clinical decision-making in everyday practice.

This study analyzed 3649 adult acute myeloid leukemia (AML) patients undergoing haploidentical stem cell transplantation (haplo-SCT) with either posttransplant cyclophosphamide (PTCy), anti-thymocyte globulin (ATG), or their combination, and showed that ATG alone had worse outcomes compared to PTCy, but combining PTCy and ATG significantly reduced acute graft-vs-host disease (GVHD) rates without affecting transplant outcomes. This suggests the PTCy and ATG combination could be a superior GVHD prophylaxis strategy in haplo-SCT for AML.